Olmesartan/Amlodipin/Hct Heumann (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxomil, the active ingredient in Olmesartan/Amlodipin/Hct Heumann, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, often when single‑agent therapy is insufficient. GNH USA supplies Olmesartan/Amlodipin/Hct Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan/Amlodipin/Hct Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipin/Hct Heumann is used to manage hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertensive heart disease: improves cardiac workload and prevents disease progression. - Chronic kidney disease with hypertension: slows renal function decline by controlling blood pressure.

Common Side Effects: - Headache: mild to moderate tension‑type headache. - Peripheral edema: swelling of ankles or feet, especially with amlodipine. - Dizziness: sensation of light‑headedness, often upon standing. - Fatigue: general tiredness without specific cause. - Cough: dry, non‑productive cough, less common than with ACE inhibitors. - Increased urination: due to the diuretic component.

Serious or Rare Side Effects: - Hyperkalemia: elevated potassium levels that may cause cardiac arrhythmia. - Acute kidney injury: sudden reduction in renal function. - Severe hypotension: marked drop in blood pressure leading to fainting. - Angio‑edema: rapid swelling of face, lips, tongue, or airway. - Liver enzyme elevation: abnormal liver function tests. - Blood dyscrasias: rare blood cell abnormalities such as agranulocytosis.

When prescribing Olmesartan/Amlodipin/Hct Heumann, clinicians should consider patient‑specific factors and monitor for adverse reactions.

- Renal impairment: adjust monitoring and avoid in severe cases. - Electrolyte disturbances: watch for low potassium or sodium levels. - Hepatic dysfunction: use with caution in patients with liver disease. - Pregnancy: contraindicated; avoid use during gestation. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan/Amlodipin/Hct Heumann may interact with several drug classes, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - Potassium‑rich supplements or salts: risk of hyper‑kalemia. - Other renin‑angiotensin system blockers (ACE inhibitors, ARBs): additive hypotensive effect. - Strong CYP3A4 inhibitors (e.g., itraconazole): increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Lithium: increased lithium levels and toxicity risk. - Diuretics other than hydrochlorothiazide: enhanced electrolyte shifts. - Antidiabetic agents: may require dose adjustment due to blood‑pressure‑related glucose changes.